Literature DB >> 32830218

A clinical-radiological framework of the right temporal variant of frontotemporal dementia.

Hulya Ulugut Erkoyun1, Colin Groot1, Ronja Heilbron1, Anne Nelissen1, Jonathan van Rossum1, Roos Jutten1, Ted Koene1, Wiesje M van der Flier1,2, Mike P Wattjes3,4, Philip Scheltens1, Rik Ossenkoppele1,5, Frederik Barkhof3,6, Yolande Pijnenburg1.   

Abstract

The concept of the right temporal variant of frontotemporal dementia (rtvFTD) is still equivocal. The syndrome accompanying predominant right anterior temporal atrophy has previously been described as memory loss, prosopagnosia, getting lost and behavioural changes. Accurate detection is challenging, as the clinical syndrome might be confused with either behavioural variant FTD (bvFTD) or Alzheimer's disease. Furthermore, based on neuroimaging features, the syndrome has been considered a right-sided variant of semantic variant primary progressive aphasia (svPPA). Therefore, we aimed to demarcate the clinical and neuropsychological characteristics of rtvFTD versus svPPA, bvFTD and Alzheimer's disease. Moreover, we aimed to compare its neuroimaging profile against svPPA, which is associated with predominant left anterior temporal atrophy. Of 619 subjects with a clinical diagnosis of frontotemporal dementia or primary progressive aphasia, we included 70 subjects with a negative amyloid status in whom predominant right temporal lobar atrophy was identified based on blinded visual assessment of their initial brain MRI scans. Clinical symptoms were assessed retrospectively and compared with age- and sex-matched patients with svPPA (n = 70), bvFTD (n = 70) and Alzheimer's disease (n = 70). Prosopagnosia, episodic memory impairment and behavioural changes such as disinhibition, apathy, compulsiveness and loss of empathy were the most common initial symptoms, whereas during the disease course, patients developed language problems such as word-finding difficulties and anomia. Distinctive symptoms of rtvFTD compared to the other groups included depression, somatic complaints, and motor/mental slowness. Aside from right temporal atrophy, the imaging pattern showed volume loss of the right ventral frontal area and the left temporal lobe, which represented a close mirror image of svPPA. Atrophy of the bilateral temporal poles and the fusiform gyrus were associated with prosopagnosia in rtvFTD. Our results highlight that rtvFTD has a unique clinical presentation. Since current diagnostic criteria do not cover specific symptoms of the rtvFTD, we propose a diagnostic tree to be used to define diagnostic criteria and call for an international validation.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  dementia; frontotemporal dementia; frontotemporal lobar degeneration; prosopagnosia; right temporal lobe atrophy

Mesh:

Year:  2020        PMID: 32830218      PMCID: PMC9172625          DOI: 10.1093/brain/awaa225

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   15.255


Introduction

Frontotemporal dementia (FTD) is a neurodegenerative disorder that predominantly affects the frontal and/or temporal lobes. Three different prototypic FTD syndromes have been described, being semantic dementia, progressive non-fluent aphasia (PNFA) and behavioural variant frontotemporal dementia (bvFTD) (Neary ). In 2011, consensus clinical diagnostic criteria were revised and FTD was classified as behavioural variant (Rascovsky ) whereas semantic dementia and PNFA were classified under the umbrella of primary progressive aphasia (PPA), including the semantic variant (svPPA), the non-fluent/agrammatic variant and the logopenic variant of PPA (Gorno-Tempini ). The typical neuroimaging pattern of bvFTD consists of frontal and/or temporal atrophy (Rascovsky ), whereas bilateral anterior temporal atrophy is suggestive of svPPA with usually a greater amount of atrophy on the left side, and predominant left posterior frontal and insular atrophy is the neuroimaging pattern of the non-fluent variant of PPA (Gorno-Tempini ). On the other hand, a number of authors have mentioned a separate syndromic variant that predominantly affects the right temporal lobe (Thompson ; Chan ). The main clinical characteristics that have been associated with the right temporal variant of frontotemporal dementia (rtvFTD) are prosopagnosia, memory deficits, getting lost and profound behavioural changes such as disinhibition and obsessive personality (Thompson ; Chan ; Josephs ; Everhart ; Kamminga ; Veronelli ; Pozueta ). Additional symptoms particularly linked to rtvFTD include hyper-religiosity, visual hallucinations and cross-modal sensory experiences (Chan ). Since the revision of consensus criteria for bvFTD (Rascovsky ) and semantic dementia being considered a variant of PPA (Gorno-Tempini ), the syndrome of rtvFTD has been relatively neglected in the literature. In the most recent diagnostic criteria (Gorno-Tempini ), bilateral anterior temporal atrophy has been the ‘imaging supported diagnostic’ criterion for svPPA, and therefore rtvFTD has been classified as svPPA. On the other hand, an early amnestic presentation and behavioural changes may fulfil clinical diagnostic criteria for either bvFTD or Alzheimer’s disease (McKhann ; Rascovsky ). Reflective of all this, there is not even agreement on its name. Over the years, the syndrome has been termed as ‘right temporal lobe atrophy’, ‘right variant FTD’, ‘temporal variant FTD’ and ‘right temporal variant of FTD’ (Gainotti ; Seeley ; Joubert ; Chan ; Henry ; Everhart ), whereas those authors who consider rtvFTD as part of semantic dementia use terms such as ‘right variant of semantic dementia’, ‘right predominant semantic dementia’ or ‘right-lateralized semantic dementia’ (Thompson ; Brambati ; Kamminga ; Kumfor ; Snowden ; Pozueta ). However, in most available clinical and radiological studies, the number of patients has been limited (n = 6–20 patients) and none of them excluded subjects with underlying Alzheimer’s disease pathology based on CSF biomarker profile or amyloid PET (Thompson ; Seeley ; Brambati ; Chan ; Kumfor ), except a single post-mortem study (Josephs ). To delineate the potentially unique clinical syndrome of rtvFTD, we set out to examine the clinical and neuropsychological profile of rtvFTD and compare it to svPPA, bvFTD, and Alzheimer’s disease. Additionally, we aimed to identify the neuroimaging pattern of rtvFTD in comparison with svPPA to establish whether these distinct clinical presentations also involve distinct anatomical underpinnings.

Materials and methods

Patient selection

Six hundred and nineteen patients with a clinical diagnosis of FTD and/or PPA whose amyloid status data were available, diagnosed between January 1998 and June 2018, were collected from the Amsterdam Dementia Cohort (van der Flier ). All patients were diagnosed by a multidisciplinary team according to clinical diagnostic criteria (Neary ; Gorno-Tempini ; Rascovsky ). Thirty-two patients who had a positive Alzheimer’s disease CSF profile (Tijms ) and/or a positive amyloid-PET scan were excluded. Our inclusion criterion was having a predominant temporal lobar atrophy on the right side on the initial brain MRI (Supplementary Fig. 1). Therefore, three patients were excluded due to lack of brain MRI scans. All MRI scans had been visually assessed by experienced neuro-radiologists (F.B., M.W.) who were blinded to clinical and paraclinical details. Based on visual assessment (Rhodius-Meester ), subjects were included in the study if temporal cortical atrophy and/or mesial temporal atrophy scores (Scheltens ) were at least more than one grade higher on the right side than on the left side. This yielded a sample of 70 subjects with right predominant temporal lobe atrophy. Hereby, 11.3% of our FTD cohort were identified as rtvFTD. The remaining 514 patients showed predominant frontal or equal bilateral temporal or predominant left temporal atrophy and were therefore not included. To elucidate the potential rtvFTD subjects in the excluded groups (patients with positive Alzheimer’s disease CSF profile and/or PET scan and patients without MRI), all initial neuroimaging of excluded subjects was also assessed. However, none of the subjects had predominant right temporal lobe atrophy. Four of the 70 rtvFTD subjects had a post-mortem pathological diagnosis showing frontotemporal lobar degeneration with tau pathology (FTLD-tau, n = 1, with a mutation in the tau gene), FTLD with TAR DNA binding protein 43 (n = 2) and FTLD with fused in sarcoma protein (n = 1). Additionally, one subject without a post-mortem examination was carrier of a pathogenic variant in the progranulin gene. To compare the clinical characteristics of the diseases, age and gender-matched, biomarker-based svPPA (n = 70), bvFTD (n = 70) and Alzheimer’s disease patients (n = 70) diagnosed between January 1998 and June 2018 were selected from the Amsterdam Dementia Cohort (van der Flier ), as control groups with an unbiased method (logistic regression model) (Hosmer, 2013). Additionally, 70 age- and sex-matched (age: 62.9 ± 8.3, 34% female) healthy volunteers and subjective cognitive decline patients from the Amsterdam Dementia Database were added as a reference for cognitive tests. For the radiological part of the study, we also selected 121 amyloid-β-negative cognitively normal subjects [age: 57.4 ± 8.9, 41% male, Mini-Mental State Examination (MMSE): 29.0 ± 0.8] from the Amsterdam Dementia Cohort. This group served as a reference in voxel-wise contrasts. Supplementary Fig. 2 displays the patient selection.

Clinical data collection and assessment

For clinical data analysis, in this retrospective study both qualitative and quantitative methods were used. The case notes written by senior neurologists Y.P. and P.S. were scrutinized and all described symptoms were extracted. Symptoms were subclassified as ‘initial symptoms’ (at the initial visit) and ‘later symptoms’ (at any stage of the disease, only rated when reported at follow-up). Similar symptoms were combined into one umbrella term by R.H. and Y.P., based on similar meaning and/or cognitive/behavioural domains (Supplementary material). Subsequently, 21 single symptoms were categorized in the following four groups; cognitive, language, behavioural, and other symptoms. All 21 symptoms were recorded as present or absent for each patient. As part of their functional assessment, the Clinical Dementia Rating Scale (CDR) was performed (Morris, 1993) in all patients. General cognitive functioning was measured using the MMSE (Folstein ), whereas executive functioning was screened with the Frontal Assessment Battery (FAB) (Dubois ). The patients’ behavioural and psychological status was assessed by the neuropsychiatric inventory (NPI) (Cummings ).

Neuropsychological assessment

Neuropsychological examination was performed for diagnostic purposes at first presentation to the Alzheimer Centre Amsterdam. A standard test battery was administered to assess multiple cognitive domains such as episodic memory [visual association test (VAT) A (Lindeboom ) and the Dutch version of the Rey Auditory Verbal Learning Test (RAVLT)], executive functions [Trail Making Test (TMT) B (Tombaugh, 2004) and digit span backward (Wechsler, 2008)], semantic memory [category fluency animals (Morris )], confrontation naming [VAT naming (Lindeboom )], attention [digit span forward (Wechsler, 2008) and TMT A (Tombaugh, 2004)] and visuospatial functions [Visual Objective and Space Perception (VOSP)–fragmented letters and VOSP–dot counting (Quental )]. Details of the clinical assessment and tests have been published previously (van der Flier ; van der Flier and Scheltens, 2018). All data for cognitive, psychological and functional assessment were collected retrospectively.

MRI acquisition and processing

MRI of the brain was acquired on a 1 T, 1.5 T or 3 T whole body magnetic resonance system (Siemens Magnetom Impact, Avanto and Sonata, GE Healthcare Signa HDXT, Discovery MR750, GE Medical Systems; Ingenuity TF PET/MR, Philips Medical Systems; Titan, Toshiba Medical Systems), using previously described protocols (Ten Kate ; Groot ). Eleven of 70 rtvFTD and 18 of 70 svPPA subjects did not have a suitable MRI available for voxel-based morphometry (VBM) analysis. MRI scans of the remaining 59 rtvFTD, 52 svPPA and 121 control subjects were collected and the structural 3D T1-weighted magnetic resonance images were segmented into grey matter, white matter and CSF volumes, which were summed to provide the total intracranial volume. Next, Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra (DARTEL) was used to generate a study-specific template by aligning grey matter images nonl-inearly to a common space in SPM12 (Wellcome Trust Centre for Neuroimaging, Institute of Neurology at University College London). Native space grey matter images were then spatially normalized to the DARTEL template using individual flow fields. Modulation was applied to preserve the total amount of signal, and images were smoothed using an 8 mm full-width at half-maximum isotropic Gaussian kernel. Visual inspection was performed after each processing step and the images of eight rtvFTD patients and six svPPA patients were excluded based on these inspections. All images of the control group were suitable for analysis. Thus, the final selection included 51 rtvFTD patients, 46 svPPA patients and 121 cognitively normal participants and the normalized, smoothed and modulated images of these subjects were used in the VBM analyses. Additionally, the automated anatomical labelling (AAL) atlas was used to extract regional grey matter volumes across 62 regions, which were used in the region of interest analyses.

Statistical analysis

Analyses were conducted using SPSS Statistics, version 24.0 (IBM) and SPM12. Differences in categorical variables between groups (rtvFTD, svPPA, bvFTD, and Alzheimer’s disease) were assessed with chi-square and continuous variables between groups were assessed with one-way ANOVA or Kruskal-Wallis variance analysis depending on the distribution of the variables based on normality test. Post hoc comparisons were corrected for multiple comparisons using the Bonferroni correction. The results were thresholded at a corrected P-value of <0.05. The combination of clinical features that were considered characteristic of rtvFTD based on chart review was reported in a diagnostic tree of rtvFTD including the negative amyloid status and its radiological features. Sensitivity, specificity, positive and negative predictive values of the clinical syndrome were calculated with cross tables with 95% confidence intervals. To identify patterns of neurodegeneration in each syndrome with respect to healthy controls we performed voxel-wise contrasts of grey matter volumes between groups (rtvFTD, svPPA) and controls using general linear models adjusted for age, sex, intracranial volume, and scanner field strength. In addition, to compare the atrophy pattern of rtvFTD and svPPA, an asymmetry index was calculated within regions of interest with the formula [AI (%) = 200 × (R − L)/(R + L)] (Ossenkoppele ). Thus, negative outcomes indicate more atrophy in the right hemisphere, while positive values reflect left lateralized asymmetry. Additionally, to identify the anatomical correlate of prosopagnosia, which was observed to be the most distinguishing symptom of rtvFTD, we compared the initial MRI scans of rtvFTD subjects with prosopagnosia (n = 37) and without prosopagnosia (n = 33) at the initial visit while adjusting for age, sex, intracranial volume, scanner field strength and whole-brain grey matter to intracranial volume ratios.

Ethical approval

The local Medical Ethics Committee approved a general protocol for using the clinical data for research purposes (Protocol No: 2016.061).

Data availability

Data are available on request from the corresponding author.

Results

Demographic data

Table 1 displays demographic data, symptom duration, follow-up duration and handedness per patient group. The rtvFTD group comprised 49 male and 21 female patients with a mean age of 64.7 years [standard deviation (SD) 8.4] and a mean symptom duration of 2.6 years (SD 1.6). Mean symptom duration and median follow-up duration did not differ significantly between diagnostic groups (P = 0.102, P = 0.666). Handedness varied among patients, but no statistical differences in the distribution of handedness per group were found (P = 0.074). To establish receptive language dominance in left-handed, ambidexter and handedness unknown subjects, we checked whether clinical symptoms showed concordance with the anatomic distribution of cortical atrophy and clinical presentation. All patients demonstrated the same pattern of hemispheric lateralization as the right-handers (Table 1).
Table 1

Demographic data, symptom and follow-up duration, and handedness per group

rtvFTDsvPPAbvFTDAD P
n 70707070
Gender, n female (%)21 (30)24 (34)25 (35)22 (31)0.885a
Age, years, mean ± SD64.7 ± 8.464.0 ± 7.663.6 ± 6.765.1 ± 7.60.470b
Handedness: left/right/ambidexterous/unknown6/57/1/61/55/0/147/51/3/98/52/0/100.074c
Symptom duration, years, mean ± SD2.6 ± 1.63.8 ± 1.44.4 ± 1.43.6 ± 4.60.102b
Follow-up period, years, median (min–max)2 (0–11)1 (1–8)2 (0–11)2 (1–7)0.666d

Chi-square.

One-way ANOVA.

Fisher’s exact test.

Kruskal-Wallis non-parametric tests.

AD = Alzheimer’s disease; SD = standard deviation.

Demographic data, symptom and follow-up duration, and handedness per group Chi-square. One-way ANOVA. Fisher’s exact test. Kruskal-Wallis non-parametric tests. AD = Alzheimer’s disease; SD = standard deviation.

Core symptoms of right temporal variant FTD

Detailed initial and later symptoms per disease group are displayed in Table 2. It should be noted that multiple symptoms could be present simultaneously in one patient, hence the total number of symptoms exceeds the number of patients.
Table 2

Clinical features of the diagnostic groups

Symptoms a Initial (% affected)
Later (% affected)
rtvFTDsvPPAbvFTDADrtvFTDsvPPAbvFTDAD
Cognitive
Memory problems60254999906776100
Prosopagnosia5421407029130
Executive dysfunction2118528358418087
Orientation problems617276634263674
Getting lost7412162061726
Visuo- spatial problems77104623112254
Language 481004379821006289
Word-finding difficulties3172307961794789
Single word comprehension deficit1861703560146
Paraphasias145131319641421
Naming difficulties2885212351873030
Behavioural 956510042979010075
Disinhibition6031812074829037
Compulsive behaviour40354617166669
Apathy or inertia5541754091618552
Loss of empathy and egocentrism501455365476420
Hyper-orality and dietary changes228501468376118
Other symptoms
Motor / mental slowness2715172770253734
Hyper-religiosity11004400
Depression271543644231144
Delusions / hallucinations77972213109
Somatic complaints and aches158201440272727
Feeling of anxiety/ panic1111112838251834

Symptoms were collected based on the case notes written by senior neurologists. For further information see the Supplementary material.

AD = Alzheimer’s disease.

Clinical features of the diagnostic groups Symptoms were collected based on the case notes written by senior neurologists. For further information see the Supplementary material. AD = Alzheimer’s disease. Episodic memory problems and prosopagnosia were two of the most common initial symptoms of rtvFTD with a prevalence of 60% and 54%, respectively, increasing to 90% and 70% during follow-up. Besides these symptoms, behavioural problems were almost universally present at the initial visit and included behavioural disinhibition (60%), apathy or inertia (55%), loss of empathy and egocentrism (50%), and compulsive behaviour (40%). The latter not only consisted of simple compulsive behaviour, such as clock watching, but also of ritualistic preoccupations, such as dressing each day of the week in a different colour, and repeatedly driving more than 1 h to the same shop, to buy objects at a minimal discount. Language problems such as word-finding difficulties (31%) and anomia (28%) were relatively less frequent at the first assessment. However, over the disease course, 82% of the cases developed language difficulties. Of note, the characteristic language symptoms of svPPA, such as single word comprehension deficits (18%) and paraphasias (14%), were recorded less frequently.

Main differences between diagnostic groups

To compare the clinical profiles of rtvFTD, svPPA, bvFTD and Alzheimer’s disease, the prominent symptoms of the disease groups were displayed against the current diagnostic criteria for bvFTD (Rascovsky ), svPPA (Gorno-Tempini ) and Alzheimer’s disease (McKhann ) on a descriptive spider graph (Fig. 1).
Figure 1

Main differences among disease groups at first assessment (initial symptoms) and at any stage of the disease (later symptoms). The shadow graphs on the background were adapted from current diagnostic criteria (Gorno-Tempini ; McKhann ; Rascovsky ). AD = Alzheimer’s disease.

Main differences among disease groups at first assessment (initial symptoms) and at any stage of the disease (later symptoms). The shadow graphs on the background were adapted from current diagnostic criteria (Gorno-Tempini ; McKhann ; Rascovsky ). AD = Alzheimer’s disease. As expected, the pattern of svPPA, bvFTD, and Alzheimer’s disease clinical symptoms were in line with their respective clinical criteria. Cases with rtvFTD were characterized by prosopagnosia, behavioural problems, language problems, and episodic memory problems, thereby combining unique features and common features with each of the comparative patient groups. During the disease course, the most prominent clinical features of rtvFTD were still not completely overlapping with one of the other groups, meaning that also during the disease course, rtvFTD kept its own clinical profile. Prosopagnosia was the most unique symptom of rtvFTD. It was not seen in Alzheimer’s disease, and much less prevalent in svPPA and bvFTD. Memory problems were most commonly present in Alzheimer’s disease, but not unique, but were also present (to a lesser extent) in rtvFTD and bvFTD, and eventually also in svPPA. Even though all bvFTD patients exhibited behavioural changes at the initial presentation, both rtvFTD (95%) and svPPA (65%) groups initially exhibited behavioural changes as well. However, the characteristics of the behavioural problems were different in rtvFTD. Compulsiveness and apathy-inertia were the most prominent behavioural changes in svPPA, whereas rtvFTD patients exhibited various and more frequent behavioural symptoms such as disinhibition, loss of empathy, as well as compulsiveness and apathy-inertia initially. Although these behavioural problems were also prominent in bvFTD, over the disease course, behavioural symptoms of rtvFTD and bvFTD showed different progression patterns, where compulsive behaviour, apathy-inertia, and hyperorality and dietary changes evolved most prominently in rtvFTD. In contrast, patients with bvFTD demonstrated greater executive dysfunction than rtvFTD. In addition, depression was more common in rtvFTD (27% initial, 44% later) than bvFTD (4% initial, 11% later). Language disorder was the prominent feature of svPPA. Even though patients with rtvFTD demonstrated relatively less frequent language problems initially, at the following visits the majority of patients developed language dysfunction. The two most common language symptoms recorded at the initial visit were word-finding difficulty and anomia for rtvFTD whereas svPPA patients exhibited highly frequent language problems with a wide range of symptom distribution such as single word comprehension deficits, paraphasias, as well as word-finding difficulties and anomia. Visuospatial and orientation problems and getting lost were more common in Alzheimer’s disease than in the FTD groups in both the initial and later stages. Even though motor/mental slowness was not common in rtvFTD at initial presentation, it became one of the distinguishing symptoms of rtvFTD during follow-up. Psychiatric features, such as depression, psychotic symptoms, and anxiety evolved during the course of rtvFTD at a higher frequency compared with the other disease groups. Somatic complaints and aches, for which no medical cause was found, were present in 40% of rtvFTD cases, compared to 27% in the other groups. In rtvFTD, these were also associated with beliefs that the body was containing valves or tubes that could be influenced from the outside. Hyper-religiosity was less common, but was uniquely observed in the rtvFTD and svPPA groups (Table 2).

Cognitive test scores and neuropsychiatric inventory

Dementia severity and neuropsychological test scores are shown per diagnostic group in Table 3. Because of a change in the test protocols used over the years, some patients’ data were not available. The numbers of data available patients are displayed in the figures and tables.
Table 3

Cognitive test scores of the diagnostic groups

HC
rtvFTD
svPPA
bvFTD
AD
One-way ANOVA
Cognitive domainTest n Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD P Group differences
Disease severityCDR49 0.6 ± 0.35370.9 ± 0.63540.8 ± 0.47490.9 ± 0.430.051NS
Global cognitionMMSE7028.9 ± 1.107025.34 ± 3.235921.08 ± 6.306725.37 ± 3.876720.22 ± 5.10 <0.001 HC > rtvFTD, bvFTD > svPPA, AD
Episodic memoryVAT-A7011.61 ± 0.715810.05 ± 2.64468.37 ± 3.735510.38 ± 2.52575.19 ± 4.06 <0.001 HC, rtvFTD, bvFTD, svPPA > AD
RAVLT delayed recall708.89 ± 2.83504.62 ± 3.34282.86 ± 2.86585.26 ± 3.33401.85 ± 02.00 <0.001 HC > rtvFTD, bvFTD, svPPA > AD
Executive functioningFAB7017.23 ± 1.134815.02 ± 3.413012.40 ± 3.745212.96 ± 4.272911.55 ± 3.56 <0.001 HC > rtvFTD>bvFTD, svPPA, AD
Digit span backward7013.91 ± 2.79598.37 ± 2.65466.70 ± 2.57587.50 ± 2.69565.88 ± 2.53 <0.001 HC > rtvFTD, bvFTD > svPPA, AD
TMT-B7081.54 ± 34.2154121.63 ± 77.1741167.10 ± 97.3651138.33 ± 72.6029220.52 ± 155.29 <0.001 HC > rtvFTD, bvFTD, svPPA > AD
LanguageVAT Naming7011.89 ± 1.11609.98 ± 2.48436.49 ± 3.805511.53 ± 1.335511.51 ± 0.76 <0.001 HC, bvFTD, AD > rtvFTD > svPPA
Animal fluency7023.7 ± 5.726014.30 ± 5.33457.58 ± 5.535714.88 ± 6.036012.37 ± 5.01 <0.001 HC > rtvFTD, bvFTD, AD > svPPA
AttentionDigit span forward7015.2 ± 3.126011.72 ± 2.914810.21 ± 3.055811.22 ± 2.935710.70 ± 3.340.061NS
TMT-A7048.7 ± 20.396354.60 ± 31.424961.55 ± 29.676156.59 ± 31.9552103.54 ± 76.91 <0.001 HC, rtvFTD, bvFTD, svPPA > AD
Visuospatial functionFragmented letters (VOSP)7019.3 ± 0.844216.62 ± 4.832317.39 ± 4.344216.62 ± 4.832415.46 ± 4.860.574NS
Dot counting (VOSP)709.8 ± 0.51399.74 ± 1.14209.55 ± 1.19399.74 ± 1.14228.55 ± 1.62 0.018 HC, rtvFTD, bvFTD, svPPA > AD

Statistically significant values (P < 0.05) are presented in bold. Group differences are displayed in the next column. AD = Alzheimer’s disease; CDR = Clinical Dementia Rating; FAB = Frontal Assessment Battery; HC = healthy control; MMSE = Mini-Mental State Examination; NS = not significant; RAVLT = Dutch version of the Rey Auditory Verbal Learning Test; SD = standard deviaiton; TMT = Trail Making Test; VAT = Visual Association Test; VOSP = Visual Objective And Space Perception.

Cognitive test scores of the diagnostic groups Statistically significant values (P < 0.05) are presented in bold. Group differences are displayed in the next column. AD = Alzheimer’s disease; CDR = Clinical Dementia Rating; FAB = Frontal Assessment Battery; HC = healthy control; MMSE = Mini-Mental State Examination; NS = not significant; RAVLT = Dutch version of the Rey Auditory Verbal Learning Test; SD = standard deviaiton; TMT = Trail Making Test; VAT = Visual Association Test; VOSP = Visual Objective And Space Perception. Dementia severity, as measured with the CDR, was lower in the rtvFTD group; however, no significant difference was detected between disease groups (P = 0.051). MMSE scores were higher in rtvFTD and bvFTD compared to svPPA and Alzheimer’s disease (P < 0.001). Alzheimer’s disease patients demonstrated greater memory impairment (VAT-A and RAVLT delayed recall P < 0.001), attention deficits (TMT-A P < 0.001, digit span forward P = 0.065) and visuospatial dysfunction (dot counting P = 0.020, fragmented letters P = 0.574) than other groups whereas language deficits were most profound in the svPPA group (VAT naming and animal fluency P < 0.001). Patients with rtvFTD exhibited similar performance to bvFTD generally, except on the naming test and FAB. The patients with rtvFTD demonstrated worse performance than bvFTD on the naming test (P < 0.001), whereas bvFTD patients exhibited greater executive dysfunction (FAB P = 0.001). As a result, rtvFTD patients exhibited a generally better performance on neuropsychological tests compared to the other diagnostic groups, except on the naming test (Table 3). On the other hand, patients with rtvFTD exhibited worse performance than cognitively normal subjects on global cognition, episodic memory, language and executive functions. NPI results showed that neuropsychiatric symptoms were most severe in patients with bvFTD, as indicated by the overall NPI score and by the scores for aberrant motor behaviour, sleep time behaviour problems, changing eating habits, irritability, aggression and disinhibition. However, a statistically significant difference was observed only in the overall NPI score and the items related with disinhibition and changing eating habits (P < 0.05, bvFTD versus other diagnostic groups). Although bvFTD has the highest overall NPI score, the item related with depression was higher in rtvFTD; however, this difference was not statistically significant (P = 0.101) (Fig. 2).
Figure 2

Neuropsychiatric inventory medians of the disease groups. AD = Alzheimer’s disease. Frequency × Severity scores were analysed. *P < 0.05, bvFTD versus other diagnostic groups.

Neuropsychiatric inventory medians of the disease groups. AD = Alzheimer’s disease. Frequency × Severity scores were analysed. *P < 0.05, bvFTD versus other diagnostic groups.

Radiological characteristics of right temporal variant FTD and comparison with semantic variant PPA

VBM analysis revealed that, compared with controls, patients with rtvFTD showed bilateral asymmetrical (right > left) grey matter volume loss in the anterior temporal lobes and in the right ventral frontal area. Right-sided grey matter loss was observed in the temporal poles, the superior, medial, and inferior temporal gyri, medial temporal lobe, insula, fusiform gyrus, angular gyrus, and supramarginal gyrus. The same regions were involved in the left temporal lobe, though to a lesser extent. Grey matter loss was also observed in the right inferior frontal gyrus, gyrus rectus, orbitofrontal cortex, with a greater degree of loss observed in the inferior orbitofrontal lobe. Patients with svPPA showed a mirrored pattern. Asymmetry index analysis showed that the frontal and temporal lobes were affected almost equally, but in opposite directions in rtvFTD and svPPA. Both in rtvFTD and svPPA, the temporal poles were the most affected areas (Fig. 3).
Figure 3

3D T-maps of the rtvFTD and svPPA and the asymmetry index.

3D T-maps of the rtvFTD and svPPA and the asymmetry index.

Clinico-radiological correlation of prosopagnosia in right temporal variant FTD

Mean symptom duration did not differ significantly between prosopagnosia present (3.4 ± 1.9 years) and absent (2.65 ± 1.5 years) groups (P = 0.445). Visual inspection of voxelwise contrasts between rtvFTD patients with and without prosopagnosia revealed that the patients with prosopagnosia showed more grey matter loss bilaterally in the temporal poles and anterior fusiform gyrus (P < 0.001, uncorrected). This association survived family-wise error correction (P < 0.05) in the left-anterior fusiform gyrus (Supplementary Fig. 3).

A diagnostic tree to identify right temporal variant FTD

Based on the combination of the literature review and our data, we summarized the core and supportive symptoms of rtvFTD and prepared a diagnostic tree including clinical and radiological features of rtvFTD and amyloid status (Fig. 4). To validate the proposed algorithm, sensitivity and specificity analysis for rtvFTD was performed against the background of the non-rtvFTD syndromes of bvFTD, svPPA, and Alzheimer’s disease. The sensitivity value of the presence of two or more core symptoms (prosopagnosia, memory deficit, and behavioural changes) was 81% whereas the specificity value was relatively low (75%). The core symptoms distinguished rtvFTD from svPPA and Alzheimer’s disease while approximately half of the bvFTD subjects met the core symptoms. However, when we added the supportive symptoms such as language problems and depression, the specificity value increased to 88% at the cost of sensitivity. Moreover, when the neuroimaging and negative amyloid status were taken into account, we reached a specificity of 100% of the characteristics of rtvFTD (Fig. 4). Details of the cases and diagnostic symptoms are displayed in the Supplementary material.
Figure 4

A diagnostic tree to identify rtvFTD. *Number of the subjects who met the proposed criteria. AD = Alzheimer’s disease.

A diagnostic tree to identify rtvFTD. *Number of the subjects who met the proposed criteria. AD = Alzheimer’s disease.

Discussion

In this large systematic, retrospective study, we identified a uniquely large cohort of patients with rtvFTD based on brain atrophy pattern and set out to determine their clinical profile. Furthermore, we investigated overlapping and distinguishing clinical features of rtvFTD compared with svPPA, bvFTD, and Alzheimer’s disease. We also studied the imaging phenotype of rtvFTD in more detail using VBM analysis and compared it with svPPA, the radiological differential diagnosis of rtvFTD. Prosopagnosia, episodic memory impairment and behavioural problems such as disinhibition, apathy, loss of empathy and compulsiveness were the most prominent initial symptoms of rtvFTD, whereas language ability was relatively spared initially, unlike in svPPA. During the progressive disease course, language problems such as word finding difficulties and anomia became the main features of the disease. None of the current diagnostic criteria for bvFTD or svPPA fitted rtvFTD. VBM analysis revealed, apart from predominant right anterior temporal atrophy, involvement of the left temporal and the right ventral frontal areas. Notably, it exhibited a radiological mirror image of svPPA. Additionally, the temporal poles and the anterior fusiform gyrus—especially on the left-side—were associated with prosopagnosia in rtvFTD. Prosopagnosia was the most unique symptom of rtvFTD. This result is consistent with expectations, as the relationship between prosopagnosia and right temporal lobe involvement has been described frequently (Gainotti ; Joubert , 2006; Thompson ; Gorno-Tempini ; Chan ; Everhart ). Thompson reported prosopagnosia in 10 of 11 cases with a right > left temporal atrophy, whereas Chan reported prosopagnosia in 60% (12 of 20 cases) of patients with rtvFTD. A possible explanation for this discrepancy is that impaired face recognition may not be mentioned as a specific problem by the patients and caregivers and specific tests for face recognition are usually not performed in general practice. Since it is not a clinical feature in one of the current diagnostic criteria for svPPA, bvFTD, and Alzheimer’s disease, it might also easily be neglected by physicians. Over the past 20 years, the general view has been that episodic memory processing is relatively intact in FTD (Neary ; Gorno-Tempini ; Rascovsky ). However, episodic memory deficit was one of the prominent presenting symptoms of rtvFTD, and its frequency increased up to 90% later on. Although Thompson found memory problems in only 27.3% of the rtvFTD patients, episodic memory deficit has been highlighted as an initial symptom of rtvFTD in a number of clinical studies and case reports (Tyrrell ; Joubert , 2006; Gorno-Tempini ; Chan ; Josephs ; Everhart ). Since the presence of amnesia remains a diagnostic exclusion criterion for FTD (Neary ; Gorno-Tempini ; Rascovsky ), the amnestic/prosopagnostic presentation of rtvFTD might easily be confused with Alzheimer’s disease in the early stages of the disease. It should be noted, however, that even though episodic memory deficit was one of the most common symptoms of rtvFTD, in line with previous studies (Pleizier ), we found that they showed better performance on memory tests than Alzheimer’s disease patients, however worse than healthy control subjects (RAVLT P < 0.001). Whereas episodic memory processing in semantic dementia and bvFTD has been studied previously (Hornberger ; Irish ), the mechanism of episodic memory deficits in rtvFTD is still unknown. Although disinhibition and apathy were the most common behavioural symptoms in both rtvFTD and bvFTD, in accordance with the findings of Kamminga , who compared clinical features between rtvFTD and bvFTD, we also found prominent language dysfunction and prosopagnosia in the rtvFTD group versus more severe executive dysfunction in bvFTD. Contrary to that study, revealing dietary changes as common in both disorders, in the present study these were initially less frequent in rtvFTD than in bvFTD. Compulsiveness was a distinct symptom observed frequently in both svPPA and rtvFTD. Another important result of our study was the loss of empathy, which was common in both rtvFTD and bvFTD, while it was relatively rare as a presenting feature in svPPA. This finding supports the argument that empathy is associated with the right frontotemporal areas (Rankin ; Kamminga ; Perry ). One of the striking results of our study was that at both initial and later stages, depression was observed more commonly in rtvFTD, with higher depression scores on the NPI than bvFTD. In addition, in line with previous studies, somatic complaints were observed prominently in rtvFTD at the follow-up visits, as well as depression (Gainotti ; Thompson ; Chan ; Everhart ). Overall, rtvFTD patients were more depressive, compulsive, somatic and they demonstrated pronounced deficits in face recognition and language, whereas patients with bvFTD exhibited disproportionate disinhibition, apathy and greater executive dysfunction. Nevertheless, the initial behavioural changes in rtvFTD can be a diagnostic issue, particularly in the early stages of the disease. Prosopagnosia and language problems distinguish rtvFTD from bvFTD and we suggest that the presence of predominant depression at the initial visit might also be helpful in differentiating the behavioural symptoms of rtvFTD and bvFTD. Language disorder was one of the important features of rtvFTD. However, unlike svPPA, language problems in rtvFTD were not prominent in the early stages of the disease. Similar to other studies, the most common language problems were word-finding difficulties and anomia in rtvFTD (Thompson ; Gorno-Tempini ; Seeley ; Joubert ; Josephs ), whereas the characteristic svPPA symptoms, such as single-word comprehension deficits, were relatively infrequent in the rtvFTD versus the svPPA. The svPPA is traditionally seen as inherently tied to language and current diagnostic criteria have been updated from this perspective (Gorno-Tempini ). Even though it has been acknowledged that language abilities are relatively spared in rtvFTD (Thompson ; Seeley ; Chan ; Josephs ; Everhart ), the syndrome is still classified as the right-sided semantic variant of progressive aphasias based on its atrophy pattern (Gorno-Tempini ). From a clinical perspective, this is incorrect, as language abilities can in fact be spared, in the context of prominent clinical features like behavioural abnormalities, memory and face recognition deficits. Besides these core symptoms, hyper-religiosity (Edwards-Lee ; Chan ; Josephs ; Everhart ; Veronelli ), getting lost (Chan ; Josephs ) and delusions (Chan ) have been reported as symptoms associated with rtvFTD. Hyper-religiosity was a symptom reported by 4% of rtvFTD patients in our study. Even though this symptom has been described as almost pathognomonic in case reports (Edwards-Lee ; Everhart ; Veronelli ), it has been reported in only ∼5–15% of the clinical studies (Thompson ; Chan ; Josephs ) and it has also been observed in svPPA patients (Thompson ). In our study, hyper-religiosity was observed in both rtvFTD and svPPA, whereas neither bvFTD nor Alzheimer’s disease patients presented it. Chan reported that getting lost was observed in 65% of patients in contrast to the low frequency (18%) of our study. An explanation of this discrepancy could be the exclusion of patients with positive amyloid pathology. Regarding delusions and visual hallucinations, although their prevalence increased during the disease course of rtvFTD, it was not a distinct symptom of rtvFTD, as was suggested by Chan . On the other hand, motor/mental slowness was a symptom in rtvFTD, which was not recorded to the same extent in svPPA, bvFTD and Alzheimer’s disease. Since clinical studies and case reports have often focused on initial symptoms, ‘slowness’ might not be mentioned as a symptom associated with rtvFTD in previous literature. However, a post-mortem-based study has revealed that over the disease course, 35% of the rtvFTD patients developed parkinsonism (Josephs ). In addition, some studies have pointed out the relationship between rtvFTD and motor neuron disease as well as parkinsonism (Davion ; Kobayashi ; Coon ; Lee ; Josephs ; Miki ). Although some authors have suggested that rtvFTD and svPPA reflect the same pathophysiological process and converge clinically within 3 years from symptom onset (Seeley ), one longitudinal study has revealed the divergent progression pattern of these two related syndromes (Kumfor ). Our results also show that rtvFTD patients might exhibit a different progression pattern than svPPA. As symptom duration at presentation and follow-up duration were comparable in rtvFTD and svPPA, this finding cannot be attributed to a hypothesized later presentation of rtvFTD. One of the key questions is whether these distinct clinical presentations have a distinct underlying atrophy pattern. To our knowledge, only three studies have assessed the atrophy pattern of rtvFTD systematically and the number of patients has been limited (n = 6–20) in these studies (Brambati ; Chan ; Kumfor ). In line with those studies, predominant anterior temporal atrophy with a greater degree on the right side was the characteristic imaging pattern of rtvFTD. However, different from those studies we found that the ipsilateral ventral frontal areas were also affected in both rtvFTD and svPPA initially. On the other hand, one longitudinal study has found that atrophy in the later stages of rtvFTD can be observed in right orbitofrontal areas (Kumfor ) whereas another study has argued that initial right anterior temporal atrophy is followed by subsequent involvement of the left temporal lobe to resemble patterns observed in svPPA (Brambati ). Although our study is not a longitudinal study, our results for the rtvFTD group showed involvement of both contralateral temporal and ipsilateral ventromedial frontal areas, in particular the inferior orbitofrontal lobe areas, which were also observed to be affected in the svPPA group. Even if rtvFTD and svPPA display a radiological mirror image initially, our results show that even in later clinical stages they do not have the same manifestation. Future studies combining longitudinal clinical and neuroimaging findings will be essential to further understand the disease course and large pathological studies will shed light on the pathophysiological basis of these related syndromes. There is a general agreement that right hemisphere damage is necessary for the occurrence of prosopagnosia (Gorno-Tempini ; Snowden ), but disagreement exists about the role of the left hemisphere (Meadows, 1974; Damasio ; De Renzi ). A recent prospective VBM study has shown that face identification is positively associated with right anterior fusiform gyrus volume in FTD (Omar ). However, in that study, only one patient had the right predominant temporal lobe atrophy characteristic of rtvFTD (Omar ). Another VBM analysis in semantic dementia has revealed that the right anterior temporal pole, the right fusiform gyrus and the right medial temporal lobe were associated with prosopagnosia in patients with semantic dementia (Josephs ). Although our results are similar to those earlier findings, we observed that the left temporal lobe, in particular the temporal pole and the fusiform area, was also associated with prosopagnosia in rtvFTD.

Strengths and limitations

Our study differs from the previous studies in one key aspect; this is the first large clinical case-control study that excludes patients with amyloid pathology and presents a small sample size of patients with genetic/pathologically verified FTD. However, there are some limitations that need to be addressed. First, the study was performed retrospectively and although symptoms were recorded systematically in our specialized memory clinic, some symptoms might have gone unnoticed because they were not specifically asked for. This might particularly be the case for the more uncommon symptoms, such as hyper-religiosity. Second, the initial visit was not the same moment in every patients’ course of the disease. Some patients were referred from another hospital for a second opinion, whereas other patients had only been showing a few symptoms for a few months before the appointment. The other limitations were the lack of a specific cognitive test for face recognition, social cognition and missing data in cognitive tests and NPI ratings, due to change of test protocols in years. Lastly, as we performed a memory-clinic based study, all of the identified cases were symptomatic, and therefore, theoretically our sensitivity and specificity analysis of the clinical characteristics accompanying predominant right temporal atrophy might be an overestimation.

Clinical relevance

Neither the Gorno-Tempini diagnostic criteria for PPA (Gorno-Tempini ), nor the Rascovsky diagnostic criteria for bvFTD (Rascovsky ) cover the initial amnestic, prosopagnostic presentation of rtvFTD. RtvFTD is a unique progressive neurodegenerative disorder that has a distinctive cognitive, behavioural and language profile and a characteristic atrophy pattern. To cover specific symptoms of rtvFTD, we prepared a diagnostic tree including the main characteristics of rtvFTD and tested its distinguishing accuracy among the various patient groups. Even though combining core and supportive symptoms decreased the sensitivity value, accompanying language problems and depression distinguished rtvFTD from bvFTD and this yielded a specificity of 88% of clinical characteristics of rtvFTD. Furthermore, it should be underscored that neuroimaging characteristics of rtvFTD distinguished it from other FTD spectrums whereas negative amyloid status was crucial for differential diagnosis of Alzheimer’s disease. Therefore, the combination of amyloid status, clinical and radiological features yielded a 100% specificity. From a clinical point of view, the high specificity value implicates that when a patient presents with behavioural problems, the characteristic symptoms of rtvFTD, such as prosopagnosia, depression and language problems, should be examined. Following the clinical assessment, the right temporal lobe should be explored on neuroimaging, and diagnoses such as Alzheimer’s disease should be rejected unless their amyloid status is highly indicative for Alzheimer’s disease. We hope that our framework will serve as a roadmap to identify these patients in a clinical setting. In the near future, multicentre studies will be needed to define diagnostic criteria for rtvFTD and establish their accuracy in prospective cohorts. Click here for additional data file.
  58 in total

1.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

2.  Atrophy progression in semantic dementia with asymmetric temporal involvement: a tensor-based morphometry study.

Authors:  S M Brambati; K P Rankin; J Narvid; W W Seeley; D Dean; H J Rosen; B L Miller; J Ashburner; M L Gorno-Tempini
Journal:  Neurobiol Aging       Date:  2007-07-02       Impact factor: 4.673

3.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

4.  Semantic dementia and the left and right temporal lobes.

Authors:  Julie S Snowden; Jennifer M Harris; Jennifer C Thompson; Christopher Kobylecki; Matthew Jones; Anna M Richardson; David Neary
Journal:  Cortex       Date:  2017-08-31       Impact factor: 4.027

5.  Corticospinal tract degeneration and temporal lobe atrophy in frontotemporal lobar degeneration TDP-43 type C pathology.

Authors:  Y Miki; H Ling; S Crampsie; C J Mummery; J D Rohrer; Z Jaunmuktane; T Lashley; J L Holton
Journal:  Neuropathol Appl Neurobiol       Date:  2019-10-30       Impact factor: 8.090

6.  Two distinct subtypes of right temporal variant frontotemporal dementia.

Authors:  K A Josephs; J L Whitwell; D S Knopman; B F Boeve; P Vemuri; M L Senjem; J E Parisi; R J Ivnik; D W Dickson; R C Petersen; C R Jack
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

7.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

Authors:  P Scheltens; D Leys; F Barkhof; D Huglo; H C Weinstein; P Vermersch; M Kuiper; M Steinling; E C Wolters; J Valk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

8.  Right Temporal Lobe Atrophy: A Case That Initially Presented as Excessive Piety.

Authors:  D Erik Everhart; Eric M Watson; Kelly L Bickel; Alexandra J Stephenson
Journal:  Clin Neuropsychol       Date:  2015-11-05       Impact factor: 3.535

9.  Structural neuroanatomy of face processing in frontotemporal lobar degeneration.

Authors:  Rohani Omar; Jonathan D Rohrer; Julia C Hailstone; Jason D Warren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-12-16       Impact factor: 10.154

10.  Visuospatial function in early Alzheimer's disease--the use of the Visual Object and Space Perception (VOSP) battery.

Authors:  Natália Bezerra Mota Quental; Sonia Maria Dozzi Brucki; Orlando Francisco Amodeo Bueno
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more
  14 in total

Review 1.  Correlations between Dual-Pathway White Matter Alterations and Language Impairment in Patients with Aphasia: A Systematic Review and Meta-analysis.

Authors:  Jie Zhang; Shuchang Zhong; Liang Zhou; Yamei Yu; Xufei Tan; Min Wu; Peng Sun; Wei Zhang; Juebao Li; Ruidong Cheng; Yanfei Wu; Yanmei Yu; Xiangming Ye; Benyan Luo
Journal:  Neuropsychol Rev       Date:  2021-03-03       Impact factor: 7.444

2.  Genetic Spectrum and Clinical Heterogeneity of Chinese Frontotemporal Dementia Patients: Data from PUMCH Dementia Cohort.

Authors:  Liling Dong; Jie Wang; Caiyan Liu; Jie Li; Chenhui Mao; Xinying Huang; Shanshan Chu; Bin Peng; Liying Cui; Jing Gao
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.

Authors:  M Marsel Mesulam; Christina A Coventry; Eileen H Bigio; Jaiashre Sridhar; Nathan Gill; Angela J Fought; Hui Zhang; Cynthia K Thompson; Changiz Geula; Tamar Gefen; Margaret Flanagan; Qinwen Mao; Sandra Weintraub; Emily J Rogalski
Journal:  Brain       Date:  2022-06-30       Impact factor: 15.255

4.  Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study.

Authors:  Alexis X Curet Burleson; Nha Trang Thu Pham; Marina Buciuc; Hugo Botha; Joseph R Duffy; Heather M Clark; Rene L Utianski; Mary M Machulda; Matthew C Baker; Rosa Rademakers; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Dement Geriatr Cogn Disord       Date:  2021-03-23       Impact factor: 2.959

5.  Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia.

Authors:  Marina Buciuc; Joseph R Duffy; Mary M Machulda; Jonathan Graff-Radford; Nha Trang Thu Pham; Peter R Martin; Matthew L Senjem; Clifford R Jack; Nilüfer Ertekin-Taner; Dennis W Dickson; Val J Lowe; Jennifer L Whitwell; Keith Anthony Josephs
Journal:  Neurology       Date:  2021-06-04       Impact factor: 11.800

6.  Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network.

Authors:  Mélanie Leroy; Maxime Bertoux; Emilie Skrobala; Elisa Mode; Catherine Adnet-Bonte; Isabelle Le Ber; Stéphanie Bombois; Pascaline Cassagnaud; Yaohua Chen; Vincent Deramecourt; Florence Lebert; Marie Anne Mackowiak; Adeline Rollin Sillaire; Marielle Wathelet; Florence Pasquier; Thibaud Lebouvier
Journal:  Alzheimers Res Ther       Date:  2021-01-08       Impact factor: 6.982

7.  The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series.

Authors:  Hulya Ulugut Erkoyun; Sven J van der Lee; Bas Nijmeijer; Rosalina van Spaendonk; Anne Nelissen; Marta Scarioni; Anke Dijkstra; Bedia Samancı; Hakan Gürvit; Zerrin Yıldırım; Fatih Tepgeç; Basar Bilgic; Frederik Barkhof; Annemieke Rozemuller; Wiesje M van der Flier; Philip Scheltens; Petra Cohn-Hokke; Yolande Pijnenburg
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Successful Combination Therapy of Trazodone and Fluvoxamine for Pica in Alzheimer's Disease: A Case Report.

Authors:  Tadashi Kanamori; Yoshiyuki Kaneko; Kouju Yamada; Masahiro Suzuki
Journal:  Front Psychiatry       Date:  2021-07-01       Impact factor: 4.157

9.  Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review.

Authors:  Hulya Ulugut; Anke A Dijkstra; Marta Scarioni; Frederik Barkhof; Philip Scheltens; Annemieke J M Rozemuller; Yolande A L Pijnenburg
Journal:  Acta Neuropathol Commun       Date:  2021-08-03       Impact factor: 7.801

10.  The natural history of primary progressive aphasia: beyond aphasia.

Authors:  Hulya Ulugut; Simone Stek; Lianne E E Wagemans; Roos J Jutten; Maria Antoinette Keulen; Femke H Bouwman; Niels D Prins; Afina W Lemstra; Welmoed Krudop; Charlotte E Teunissen; Bart N M van Berckel; Rik Ossenkoppele; Frederik Barkhof; Wiesje M van der Flier; Philip Scheltens; Yolande A L Pijnenburg
Journal:  J Neurol       Date:  2021-07-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.